Evaluation of the Safety, Tolerability and Immunogenicity of ShigETEC, an Oral Live Attenuated Shigella-ETEC Vaccine in Placebo-Controlled Randomized Phase 1 Trial
Authors:
- Petra GirardiPGPetra Girardi
- Shushan HarutyunyanSHShushan Harutyunyan
- Irene NeuhauserINIrene Neuhauser
- Katharina GlaningerKGKatharina Glaninger
- Orsolya KordaOKOrsolya Korda
- Gábor NagyGNGábor Nagy
- Eszter NagyENEszter Nagy
- Valéria SzijártóVSValéria Szijártó
- Denes PallDPDenes Pall
- Krisztina SzarkaKSKrisztina Szarka
- Gábor KardosGKGábor Kardos
- Tamás HenicsTHTamás Henics
Open Access
Abstract
Background: Shigella spp. and enterotoxigenic Escherichia coli (ETEC) cause high morbidity and mortality worldwide, yet no licensed vaccines are available to prevent corresponding infections. A live attenuated non-invasive Shigella vaccine strain lacking LPS O-antigen and expressing the ETEC toxoids, named ShigETEC was characterized previously in non-clinical studies. Methods: ShigETEC was evaluated in a two-staged, randomized, double-blind and placebo-controlled Phase I clinical trial. A single dose of increasing amounts of the vaccine was given to determine the maximum tolerated dose and increasing number of immunizations were administered with an interval based on the duration of shedding observed. Results: Oral immunization with ShigETEC was well tolerated and safe up to 4-time dosing with 5 × 1010 colony forming units. ShigETEC induced robust systemic immune responses against the Shigella vaccine strain, with IgA serum antibody dominance, as well as mucosal antibody responses evidenced by specific IgA in stool samples and in ALS (Antibodies in Lymphocyte Supernatant). Anti- ETEC toxin responses were detected primarily in the 4-times immunized cohort and for the heat-labile toxin correlated with neutralizing capacity. Conclusion: ShigETEC is a promising vaccine candidate that is scheduled for further testing in controlled human challenge studies for efficacy as well as in children in endemic setting for safety and immunogenicity.Keywords
Funding Information
- Wellcome (212399/C/18/Z)
- European Union's Horizon 2020 Research and Innovation program (815568)
This publication has 15 references indexed in Scilit:
- Burden of enterotoxigenic Escherichia coli and shigella non-fatal diarrhoeal infections in 79 low-income and lower middle-income countries: a modelling analysisThe Lancet Global Health, 2019
- Travelers’ diarrhea: update on the incidence, etiology and risk in military and similar populations – 1990-2005 versus 2005–2015, does a decade make a difference?Tropical Diseases, Travel Medicine and Vaccines, 2019
- Morbidity and mortality due to shigella and enterotoxigenic Escherichia coli diarrhoea: the Global Burden of Disease Study 1990–2016The Lancet Infectious Diseases, 2018
- Status of vaccine research and development for ShigellaVaccine, 2016
- Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control studyThe Lancet, 2013
- Molecular mechanisms of enterotoxigenic Escherichia coli infectionMicrobes and Infection, 2010
- Prevalence of the sat, set and sen genes among diverse serotypes of Shigella flexneri strains isolated from patients with acute diarrhoeaClinical Microbiology and Infection, 2004
- HLA-B27-Associated Reactive Arthritis: Pathogenetic and Clinical ConsiderationsClinical Microbiology Reviews, 2004
- Virulence phenotype and genetic characteristics of the T32-ISTRATI Shigella flexneri 2a vaccine strainVaccine, 1991
- Efficiency of immunoprophylaxis and immunotherapy by live dysentery vaccine administration in children and adults collectivities.1982